2 completed, 1 recruiting, 1 withdrawn. 4 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 2, Recruiting 1, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow Fasting: new trials by email Literature Review of Fasting trials Research Report on Fasting
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting Orforglipron - Diabetes Mellitus, Type 2, Diabetes Melletus | Phase 3 | Recruiting | Eli Lilly and Company | 130 | 2026-07-15 | 2026-10-08 |
| Doravirine and Weight Gain in Antiretroviral Naive DOR/3TC/TDF, DOR + FTC/TAF, BIC/FTC/TAF - Body Weight Changes, Human Immunodeficiency Virus | Phase 3 | Withdrawn | Prism Health North Texas | 2022-08-01 | 2023-05-12 | |
| Residual Gastric Volume After the Ingestion of a Beverage Containing Carbohydrates Plus Whey Protein Carbohydrate plus whey protein enriched drink - Peptic Ulcer, Gastritis | Phase 2 / Phase 3 | Completed | Federal University of Mato Grosso | 30 | 2013-02-01 | 2013-04-10 |
| Double-Blind Comparison Between Mitiglinide and Nateglinide in Type 2 Diabetic Patients Mitiglinide - Diabetes | Phase 3 | Completed | Kissei Pharmaceutical Co., Ltd. | 291 | 2006-08-01 | 2008-10-21 |
Acquired Immunodeficiency Syndrome (1) · Behavior (1) · Body Weight Changes (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Endocrine System Diseases (1) · Feeding Behavior (1) · Gastritis (1) · Glucose Metabolism Disorders (1) · Insulin Resistance (1) · Metabolic Diseases (1) · Metabolic Syndrome (1) · Nutritional and Metabolic Diseases (1) · Obesity (1)
Behavior (3) · Feeding Behavior (3) · Glucose Metabolism Disorders (2) · Hyperinsulinism (2) · Metabolic Diseases (2) · Nutritional and Metabolic Diseases (2) · Behavior, Animal (1) · Blood-Borne Infections (1) · Body Weight (1) · Communicable Diseases (1) · Diabetes Mellitus (1) · Digestive System Diseases (1) · Duodenal Diseases (1) · Endocrine System Diseases (1) · Gastroenteritis (1)
Carbohydrates (1) · Receptors, Opioid, delta (1) · bictegravir, emtricitabine, tenofovir alafenamide, drug combination (1) · doravirine (1) · emtricitabine tenofovir alafenamide (1) · mitiglinide (1) · orforglipron (1)
Eli Lilly and Company (1) · Federal University of Mato Grosso (1) · Kissei Pharmaceutical Co., Ltd. (1) · Prism Health North Texas (1)
Brazil (1) · India (1) · Saudi Arabia (1) · South Africa (1) · United Arab Emirates (1) · United States (1)
Roger Bedimo (1) · Xin Gao, Professor (1)